



UNITED STAT DEPARTMENT OF COMMERCE

Patent and Trademark Office

Address: COMMISSIONER OF PATENTS AND TRADEMARKS Washington, D.C. 20231

FIRST NAMED INVENTOR ATTORNEY DOCKET NO. APPLICATION NO. **FILING DATE** 09/495,278 01/31/00 **AMEER** G 0492611-0364 **EXAMINER** HM12/1001 Choate, Hall & Stewart PAPER NUMBER **ART UNIT** Exchange Place 53 State Street Boston MA 02109-2891 1633 **DATE MAILED:**

Please find below and/or attached an Office communication concerning this application or proceeding.

Commissioner of Patents and Trademarks

10/01/01

BEST AVAILABLE COP

		Application	No.	Applicant(s)	
Office Action Summary		09/495,278		AMEER ET AL.	
		Examiner		Art Unit	
		Deborah C	lark	1633	
The MAILING DATE of this communication appears on the cover sheet with the correspondence address					
Period for Reply A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 1 MONTH(S) FROM THE MAILING DATE OF THIS COMMUNICATION. - Extensions of time may be available under the provisions of 37 CFR 1.136(a). In no event, however, may a reply be timely filed					
after SIX (6) MONTHS from the mailing date of this communication. If the period for reply specified above is less than thirty (30) days, a reply within the statutory minimum of thirty (30) days will be considered timely. If NO period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication. Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133). Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b).					
Status					
1)					
2a)□	,—	his action is non-final.			
3) Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under <i>Ex parte Quayle</i> , 1935 C.D. 11, 453 O.G. 213.					
Disposition of Claims					
4)⊠ Claim(s) <u>1-49</u> is/are pending in the application.					
4a) Of the above claim(s) is/are withdrawn from consideration.					
5) Claim(s) is/are allowed.					
6) Claim(s) is/are rejected.					
7)	7) Claim(s) is/are objected to.				
8) Claim(s) <u>1-49</u> are subject to restriction and/or election requirement.					
Application Papers					
9) The specification is objected to by the Examiner.					
10) The drawing(s) filed on is/are: a) accepted or b) objected to by the Examiner.					
Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).					
11) The proposed drawing correction filed on is: a) approved b) disapproved by the Examiner.					
If approved, corrected drawings are required in reply to this Office action.					
12) The oath or declaration is objected to by the Examiner.					
Priority under 35 U.S.C. §§ 119 and 120					
13) Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).					
a) All b) Some * c) None of:					
1. Certified copies of the priority documents have been received.					
2. Certified copies of the priority documents have been received in Application No					
 3. Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)). * See the attached detailed Office action for a list of the certified copies not received. 					
14) Acknowledgment is made of a claim for domestic priority under 35 U.S.C. § 119(e) (to a provisional application).					
a) The translation of the foreign language provisional application has been received.					
15) Acknowledgment is made of a claim for domestic priority under 35 U.S.C. §§ 120 and/or 121. Attachment(s)					
1) Notice of References Cited (PTO-892) 4) Interview Summary (PTO-413) Paper No(s)					
2) Notic	e of Draftsperson's Patent Drawing Review (PTO-948) nation Disclosure Statement(s) (PTO-1449) Paper No(s)	5		atent Application (PTO-152)	

Application/Control Number: 09/495,278

Art Unit: ***

DETAILED ACTION

The previous election/restriction mailed on 06/04/01 is vacated and replaced by the following election/restriction.

The examiner of the application has changed. The application is currently being examined by Supervisory Patent Examiner Deborah Clark, Art Unit 1633.

Election/Restrictions

Restriction to one of the following inventions is required under 35 U.S.C. 121:

- I. Claims 1-16, drawn to a method of polymerization, classified in class 424, subclass 422.
- II. Claim 17-24, 26, 28-47 and 49 drawn to a method of drug delivery, compositions of polymerizable material and a system for drug delivery classifiable in class 424, subclasses 78.17 and 280.1.
 - III. Claims 25, 27-40, 48 and 49 drawn to a method of tissue engineering, compositions of polymerizable material and a system for tissue engineering classified in class 424, subclass 78.17 and 280.1.

Claims 27-40 and 49 link(s) the inventions of Group I and Group II. The restriction requirement between the linked inventions is subject to the nonallowance of the linking claim(s), 27-40 and 49. Upon the allowance of the linking claim(s), the restriction requirement as to the linked inventions shall be withdrawn and any claim(s)

Art Unit: ***

depending from or otherwise including all the limitations of the allowable linking claim(s) will be entitled to examination in the instant application. Applicant(s) are advised that if any such claim(s) depending from or including all the limitations of the allowable linking claim(s) is/are presented in a continuation or divisional application, the claims of the continuation or divisional application may be subject to provisional statutory and/or nonstatutory double patenting rejections over the claims of the instant application.

Where a restriction requirement is withdrawn, the provisions of 35 U.S.C. 121 are no longer applicable. See *In re Ziegler*, 44 F.2d 1211, 1215, 170 USPQ 129, 131-32 (CCPA 1971). See also MPEP § 804.01.

Upon the election of Group II an election of species is also required. Group II is drawn to the patentabley distinct species: diagnostic agents and therapeutic/prophylactic agents (see claim 17). Applicant must select either diagnostic agents or therapeutics/prophylactic agents for further prosecution on the merits.

Applicant is required under 35 U.S.C. 121 to elect a single disclosed species, even though this requirement is traversed.

It is further noted that number a number of bioactive agents or drugs are disclosed in the specification intended for use in combination with the invention(s). The agents or drugs fall into the following patentabley distinct species: Proteins, antibodies, DNA encoding proteins, oligonucleotides, and small organic molecules. Upon election

~ Clot

Application/Control Number: 09/495,278

Art Unit: ***

of small organic molecules, applicants must elect an ultimate species for examination.

An organic compound is not an ultimate species.

Upon election of Group II applicant is further required under 35 U.S.C. 121 to elect a single disclosed species from the group: proteins, antibodies, DNA encoding proteins, oligonucleotides or small organic molecules for prosecution on the merits.

It is further noted that the methods of use will be examined along with the products as long as the patentability depends upon the 3 components. However, if patentability should depend upon other considerations a further restriction may be required.

Should applicant traverse on the ground that the species are not patentably distinct, applicant should submit evidence or identify such evidence now of record showing the species to be obvious variants or clearly admit on the record that this is the case. In either instance, if the examiner finds one of the inventions unpatentable over the prior art, the evidence or admission may be used in a rejection under 35 U.S.C. 103(a) of the other invention.

Applicant is advised that the reply to this requirement to be complete must include an election of the invention to be examined even though the requirement be traversed (37 CFR 1.143).

Applicant is reminded that upon the cancellation of claims to a non-elected

invention, the inventorship must be amended in compliance with 37 CFR 1.48(b) if one

or more of the currently named inventors is no longer an inventor of at least one claim

remaining in the application. Any amendment of inventorship must be accompanied by

a petition under 37 CFR 1.48(b) and by the fee required under 37 CFR 1.17(i).

Any inquiry concerning this communication or earlier communications from the

examiner should be directed to Deborah Clark whose telephone number is 703-305-

4051. The fax phone number for the organization where this application or proceeding

is assigned is 703-308-4242.

Inquiries of a general nature or relating to the status of this application or

proceeding should be directed to the receptionist whose telephone number is 703-308-

1234. Questions regarding review of formality issues may be directed to Kim Davis, the

patent analyst assisting in this application. She may be reached at 703-305-3015.

DEBORAH J. R. CLARK JPERVISORY PATENT EXAMINE

TECHNOLOGY CENTER 1800